Regeneron Pharmaceuticals (REGN) R&D In Process: 2021-2025
Historic R&D In Process for Regeneron Pharmaceuticals (REGN) over the last 4 years, with Sep 2025 value amounting to $83.1 million.
- Regeneron Pharmaceuticals' R&D In Process rose 47.86% to $83.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.2 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $101.0 million for FY2024, which is 45.73% down from last year.
- Regeneron Pharmaceuticals' R&D In Process amounted to $83.1 million in Q3 2025, which was up 731.00% from $10.0 million recorded in Q2 2025.
- In the past 5 years, Regeneron Pharmaceuticals' R&D In Process ranged from a high of $197.0 million in Q2 2022 and a low of $7.1 million during Q1 2024.
- Moreover, its 3-year median value for R&D In Process was $26.9 million (2023), whereas its average is $39.2 million.
- Its R&D In Process has fluctuated over the past 5 years, first skyrocketed by 99.64% in 2023, then plummeted by 87.34% in 2024.
- Over the past 5 years, Regeneron Pharmaceuticals' R&D In Process (Quarterly) stood at $48.0 million in 2021, then tumbled by 37.50% to $30.0 million in 2022, then remained steady at $30.0 million in 2023, then crashed by 54.00% to $13.8 million in 2024, then skyrocketed by 47.86% to $83.1 million in 2025.
- Its R&D In Process stands at $83.1 million for Q3 2025, versus $10.0 million for Q2 2025 and $12.3 million for Q1 2025.